PALI
Palisade Bio, Inc.·Healthcare
1.82
8.081%(−0.16)
Market ClosedLast Updated: — ET
52W L: $0.5352W H: $2.64
PALI NEWS
defenseworld.net
8h ago
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on
globenewswire.com
3d ago
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Needham & Co. 25th Annual Healthcare Conference, being held in a virtual format April 14–17, 2026. The Company's virtual presentation is scheduled for Thursday, April 16, 2026, from 2:15 PM to 2:55 PM ET in Track 3.
globenewswire.com
Mar 30
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement, with a 47.5% reduction in SES-CD score and 40% of patients achieving endoscopic response and 40% of patients achieving endoscopic remission Pharmacokinetic and pharmacodynamic data from ileal tissue and plasma support once-daily oral dosing for Crohn's disease showing IC90 coverage, with correlation to accepted inflammatory biomarkers Data support expansion into broader luminal CD, an indication that has regulatory clarity, more than doubles the total addressable patient population, and has no anatomical constraints Company plans to advance PALI-2108 into a Phase 2 trial in moderate to severe Crohn's disease, including evaluation of anti-fibrotic effects earlier in the disease course Company to host webcast March 31 st at 8:00 AM ET – Access the webcast here Carlsbad, CA, March 30, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the ileum and colon, today announced positive topline data from its Phase 1b clinical study evaluating PALI-2108, a first-in-class, once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, in patients with fibrostenotic Crohn's disease (FSCD). This Phase 1b study demonstrated favorable safety and tolerability, robust pharmacodynamic target engagement in ileal tissue, and encouraging early signals of clinical activity in the five participating patients.
seekingalpha.com
Mar 23
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating
I initiate Palisade Bio with a speculative buy, citing its differentiated microbiome-activated PDE4 inhibitor, PALI-2108, targeting IBD. PALI-2108's phase 1 data show promising efficacy, mechanistic engagement, and improved tolerability versus systemic PDE4 inhibitors, supporting further development. PALI's $133M cash position provides 3–4 years of runway, mitigating near-term financing risk for advancing into pivotal phase 2 trials.
defenseworld.net
Mar 20
Palisade Bio, Inc. (NASDAQ:PALI) Receives $13.25 Average Price Target from Analysts
Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy
globenewswire.com
Mar 2
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care Conference Date/time: March 2, 2026 at 3:10 PM EST Location: Boston Mariott Copley Place, Boston, MA Format: In-person presentation & investor meetings Webcast link: Register here Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting.
